Novartis CAN-Covid Trial on Coronavirus Patients Didn't Meet Primary, Secondary Endpoints
November 06 2020 - 2:12AM
Dow Jones News
By Cecilia Butini
Novartis AG said Friday that its phase 3 CAN-Covid clinical
trial evaluating the safety of a monoclonal antibody in
hospitalized patients with Covid-19 pneumonia and cytokine release
syndrome didn't meet its primary and secondary endpoints.
The study's primary endpoint was to demonstrate that the drug,
canakinumab, plus standard of care gave patients a greater chance
of survival without needing mechanic ventilation. The secondary
endpoint was the reduction of Covid-19-related deaths during the
four-week period following treatment.
The Swiss pharmaceutical major said the drug, the commercial
name of which is Ilaris, remains an effective treatment for its
approved indications, which include the treatment of a number of
rare auto-inflammatory diseases.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
November 06, 2020 01:57 ET (06:57 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From Sep 2023 to Sep 2024